Biostax(BTAX)
$0.000.00 (0.00%)
BTAX
Biostax financials statements
$0.00
At close:0.00 (0.00%)
Biostax (BTAX) Ratios
11 Followers
Biostax Ratios
BTAX's free cash flow for Q1 2024 was $-33.31K. For the 2024 fiscal year, BTAX's free cash flow was increased by $0.00 and operating cash flow was $-33.31K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|
| Liquidity Ratios | |||
| Net Current Asset Value | $ -4.53M | $ -3.33M | $ -11.67M |
| Leverage Ratios | |||
| Net Debt to EBITDA | -0.51 | -0.16 | 1.37 |
| Profitability Margins | |||
| Return on Assets (ROA) | -6695.90% | -366.92% | 15619.08% |
| Return on Equity (ROE) | 52.18% | 140.69% | -13.62% |
| Return on Capital Employed (ROCE) | 32.80% | 46.29% | 7.60% |
| Return on Invested Capital (ROIC) | 43.69% | 64.03% | 10.05% |
| Return on Tangible Assets | -6695.90% | -1757.33% | 15619.08% |
| Earnings Yield | -40.39% | -16.24% | 23.74% |
| Efficiency Ratios | |||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||
| Free Cash Flow Yield | -6.98% | -4.97% | -2.87% |
| Valuation Ratios | |||
| Enterprise Value | 6.95M | 22.32M | 9.53M |
| EV to EBITDA | -3.25 | -6.54 | 4.60 |
| EV to Sales | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -17.03 | -20.63 | -49.63 |
| EV to Operating Cash Flow | -17.03 | -38.36 | -49.63 |
| Tax and Other Ratios | |||
| Tax Burden | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.08 | 1.04 | 0.77 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.17 | 0.16 | -0.12 |
Currency in USD

